Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children

David I. Bernstein, Roger I. Glass, George Rodgers, Bruce L. Davidson, David Allen Sack

Research output: Contribution to journalArticle

Abstract

To determine the safety and relative efficacy of two reassortant rhesus rotavirus vaccines over two rotavirus seasons. —A prospective, double-masked, placebo-controlled trial. —Twenty-three centers in the United States. —A total of 1006 healthy infants between 4 and 26 weeks of age were enrolled, and 898 received three doses of vaccine or placebo. —Reactogenicity was determined by comparing the incidence of fever, diarrhea, and/or vomiting for 5 days after each dose of vaccine. Rotavirus IgA and neutralizing antibody to rhesus rotavirus and four rotavirus serotypes were measured in a subset of subjects. Relative efficacy was determined by comparing the incidence of rotavirus gastroenteritis after three doses of vaccine or placebo over two rotavirus seasons. —Adverse reactions were mild and limited to a small but significant increase in the incidence of fever after the first dose of tetravalent but not monovalent vaccine. The relative efficacy against rotavirus disease over the 2 years of observation was 40% (98.3% confidence interval, 7% to 62%) for the monovalent and 57% (98.3% confidence interval, 29% to 74%) for the tetravalent vaccine. In post hoc analyses, the relative efficacy against very severe rotavirus gastroenteritis was 73% and 82% for monovalent and tetravalent vaccine recipients, respectively. Also, a 67% and 78% reduction in medical visits for rotavirus gastroenteritis was observed. Both vaccines protected against disease caused by serotype 1 rotavirus, but only the tetravalent vaccine reduced the incidence of disease caused by non— serotype 1 rotavirus infection detected in the second season. It is unclear, however, whether this result represents serotype-specific protection or a difference in the duration of protection. —Vaccination with both vaccines was safe and significantly reduced the incidence of rotavirus gastroenteritis, but only the tetravalent vaccine provided protection against disease caused by non—serotype 1 rotaviruses during the second year of follow-up. (JAMA. 1995;273:1191-1196).

Original languageEnglish (US)
Pages (from-to)1191-1196
Number of pages6
JournalJournal of the American Medical Association
Volume273
Issue number15
DOIs
StatePublished - 1995

Fingerprint

Rotavirus
Vaccines
Gastroenteritis
Incidence
Placebos
Fever
Confidence Intervals
Rotavirus Infections
Neutralizing Antibodies
Immunoglobulin A
Vomiting
Diarrhea
Vaccination
Observation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children. / Bernstein, David I.; Glass, Roger I.; Rodgers, George; Davidson, Bruce L.; Sack, David Allen.

In: Journal of the American Medical Association, Vol. 273, No. 15, 1995, p. 1191-1196.

Research output: Contribution to journalArticle

Bernstein, David I. ; Glass, Roger I. ; Rodgers, George ; Davidson, Bruce L. ; Sack, David Allen. / Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children. In: Journal of the American Medical Association. 1995 ; Vol. 273, No. 15. pp. 1191-1196.
@article{43ac95cb7cba4d33829e195e5b381e27,
title = "Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children",
abstract = "To determine the safety and relative efficacy of two reassortant rhesus rotavirus vaccines over two rotavirus seasons. —A prospective, double-masked, placebo-controlled trial. —Twenty-three centers in the United States. —A total of 1006 healthy infants between 4 and 26 weeks of age were enrolled, and 898 received three doses of vaccine or placebo. —Reactogenicity was determined by comparing the incidence of fever, diarrhea, and/or vomiting for 5 days after each dose of vaccine. Rotavirus IgA and neutralizing antibody to rhesus rotavirus and four rotavirus serotypes were measured in a subset of subjects. Relative efficacy was determined by comparing the incidence of rotavirus gastroenteritis after three doses of vaccine or placebo over two rotavirus seasons. —Adverse reactions were mild and limited to a small but significant increase in the incidence of fever after the first dose of tetravalent but not monovalent vaccine. The relative efficacy against rotavirus disease over the 2 years of observation was 40{\%} (98.3{\%} confidence interval, 7{\%} to 62{\%}) for the monovalent and 57{\%} (98.3{\%} confidence interval, 29{\%} to 74{\%}) for the tetravalent vaccine. In post hoc analyses, the relative efficacy against very severe rotavirus gastroenteritis was 73{\%} and 82{\%} for monovalent and tetravalent vaccine recipients, respectively. Also, a 67{\%} and 78{\%} reduction in medical visits for rotavirus gastroenteritis was observed. Both vaccines protected against disease caused by serotype 1 rotavirus, but only the tetravalent vaccine reduced the incidence of disease caused by non— serotype 1 rotavirus infection detected in the second season. It is unclear, however, whether this result represents serotype-specific protection or a difference in the duration of protection. —Vaccination with both vaccines was safe and significantly reduced the incidence of rotavirus gastroenteritis, but only the tetravalent vaccine provided protection against disease caused by non—serotype 1 rotaviruses during the second year of follow-up. (JAMA. 1995;273:1191-1196).",
author = "Bernstein, {David I.} and Glass, {Roger I.} and George Rodgers and Davidson, {Bruce L.} and Sack, {David Allen}",
year = "1995",
doi = "10.1001/jama.1995.03520390051032",
language = "English (US)",
volume = "273",
pages = "1191--1196",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - Evaluation of Rhesus Rotavirus Monovalent and Tetravalent Reassortant Vaccines in US Children

AU - Bernstein, David I.

AU - Glass, Roger I.

AU - Rodgers, George

AU - Davidson, Bruce L.

AU - Sack, David Allen

PY - 1995

Y1 - 1995

N2 - To determine the safety and relative efficacy of two reassortant rhesus rotavirus vaccines over two rotavirus seasons. —A prospective, double-masked, placebo-controlled trial. —Twenty-three centers in the United States. —A total of 1006 healthy infants between 4 and 26 weeks of age were enrolled, and 898 received three doses of vaccine or placebo. —Reactogenicity was determined by comparing the incidence of fever, diarrhea, and/or vomiting for 5 days after each dose of vaccine. Rotavirus IgA and neutralizing antibody to rhesus rotavirus and four rotavirus serotypes were measured in a subset of subjects. Relative efficacy was determined by comparing the incidence of rotavirus gastroenteritis after three doses of vaccine or placebo over two rotavirus seasons. —Adverse reactions were mild and limited to a small but significant increase in the incidence of fever after the first dose of tetravalent but not monovalent vaccine. The relative efficacy against rotavirus disease over the 2 years of observation was 40% (98.3% confidence interval, 7% to 62%) for the monovalent and 57% (98.3% confidence interval, 29% to 74%) for the tetravalent vaccine. In post hoc analyses, the relative efficacy against very severe rotavirus gastroenteritis was 73% and 82% for monovalent and tetravalent vaccine recipients, respectively. Also, a 67% and 78% reduction in medical visits for rotavirus gastroenteritis was observed. Both vaccines protected against disease caused by serotype 1 rotavirus, but only the tetravalent vaccine reduced the incidence of disease caused by non— serotype 1 rotavirus infection detected in the second season. It is unclear, however, whether this result represents serotype-specific protection or a difference in the duration of protection. —Vaccination with both vaccines was safe and significantly reduced the incidence of rotavirus gastroenteritis, but only the tetravalent vaccine provided protection against disease caused by non—serotype 1 rotaviruses during the second year of follow-up. (JAMA. 1995;273:1191-1196).

AB - To determine the safety and relative efficacy of two reassortant rhesus rotavirus vaccines over two rotavirus seasons. —A prospective, double-masked, placebo-controlled trial. —Twenty-three centers in the United States. —A total of 1006 healthy infants between 4 and 26 weeks of age were enrolled, and 898 received three doses of vaccine or placebo. —Reactogenicity was determined by comparing the incidence of fever, diarrhea, and/or vomiting for 5 days after each dose of vaccine. Rotavirus IgA and neutralizing antibody to rhesus rotavirus and four rotavirus serotypes were measured in a subset of subjects. Relative efficacy was determined by comparing the incidence of rotavirus gastroenteritis after three doses of vaccine or placebo over two rotavirus seasons. —Adverse reactions were mild and limited to a small but significant increase in the incidence of fever after the first dose of tetravalent but not monovalent vaccine. The relative efficacy against rotavirus disease over the 2 years of observation was 40% (98.3% confidence interval, 7% to 62%) for the monovalent and 57% (98.3% confidence interval, 29% to 74%) for the tetravalent vaccine. In post hoc analyses, the relative efficacy against very severe rotavirus gastroenteritis was 73% and 82% for monovalent and tetravalent vaccine recipients, respectively. Also, a 67% and 78% reduction in medical visits for rotavirus gastroenteritis was observed. Both vaccines protected against disease caused by serotype 1 rotavirus, but only the tetravalent vaccine reduced the incidence of disease caused by non— serotype 1 rotavirus infection detected in the second season. It is unclear, however, whether this result represents serotype-specific protection or a difference in the duration of protection. —Vaccination with both vaccines was safe and significantly reduced the incidence of rotavirus gastroenteritis, but only the tetravalent vaccine provided protection against disease caused by non—serotype 1 rotaviruses during the second year of follow-up. (JAMA. 1995;273:1191-1196).

UR - http://www.scopus.com/inward/record.url?scp=0028964834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028964834&partnerID=8YFLogxK

U2 - 10.1001/jama.1995.03520390051032

DO - 10.1001/jama.1995.03520390051032

M3 - Article

VL - 273

SP - 1191

EP - 1196

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 15

ER -